S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VERU

Veru (VERU) Stock Price, News & Analysis

$0.70
+0.05 (+7.69%)
(As of 03/28/2024 ET)
Today's Range
$0.69
$0.77
50-Day Range
$0.37
$0.70
52-Week Range
$0.36
$1.52
Volume
5.91 million shs
Average Volume
1.01 million shs
Market Capitalization
$96.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Veru MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
257.1% Upside
$2.50 Price Target
Short Interest
Bearish
6.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Veru in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.59 out of 5 stars

Medical Sector

744th out of 938 stocks

Pharmaceutical Preparations Industry

335th out of 421 stocks

VERU stock logo

About Veru Stock (NASDAQ:VERU)

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Stock Price History

VERU Stock News Headlines

Veru Reschedules Annual Meeting of Shareholders
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Wynwood offices targeted in $102M foreclosure
VERU Mar 2024 0.500 put
VERU Mar 2024 1.500 put
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
VERU Jan 2025 17.000 call
VERU Mar 2024 0.500 call
VERU Mar 2024 3.000 put
VERU Mar 2024 2.500 put
VERU Feb 2024 0.500 call
The 3 Best Penny Stocks to Buy in February 2024
VERU Apr 2024 3.000 call
VERU Feb 2024 1.000 call
VERU Jul 2024 2.000 call
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript
Q1 2024 Veru Inc Earnings Call
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/02/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
189
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+185.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
3 Analysts

Profitability

Net Income
$-93,090,000.00
Net Margins
-571.20%
Pretax Margin
-568.26%

Debt

Sales & Book Value

Annual Sales
$16.30 million
Book Value
$0.20 per share

Miscellaneous

Free Float
118,075,000
Market Cap
$96.35 million
Optionable
Optionable
Beta
-0.23
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Mitchell S. Steiner F.A.C.S. (Age 63)
    M.D., Chairman, President & CEO
    Comp: $885.32k
  • Dr. Harry Fisch F.A.C.S. (Age 65)
    M.D., Vice Chairman & Chief Corporate Officer
  • Ms. Michele Greco (Age 65)
    CFO & Chief Administrative Officer
    Comp: $493.7k
  • Dr. K. Gary Barnette Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $676.27k
  • Mr. Samuel Fisch
    Executive Director of Investor Relations & Corporate Communications
  • Mr. Michael J. Purvis
    Executive VP, General Counsel & Corporate Strategy and Secretary
  • Mr. Kevin J. Gilbert CPA
    J.D., Executive Vice President of Corporate Development
  • Mr. Martin Tayler (Age 55)
    Executive Vice President of FC2 Global Operations
    Comp: $180.51k
  • Mr. Philip R. Greenberg J.D.
    Executive VP & Deputy General Counsel
  • Dr. Domingo Rodriguez M.D. (Age 62)
    Executive Vice President of Global Clinical Operations

VERU Stock Analysis - Frequently Asked Questions

Should I buy or sell Veru stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price target for 2024?

3 brokers have issued 1-year target prices for Veru's stock. Their VERU share price targets range from $2.00 to $3.00. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 257.1% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2024?

Veru's stock was trading at $0.72 at the beginning of 2024. Since then, VERU shares have decreased by 2.8% and is now trading at $0.7001.
View the best growth stocks for 2024 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERU earnings forecast
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) announced its quarterly earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. The business had revenue of $15.65 million for the quarter, compared to analyst estimates of $18.26 million. Veru had a negative trailing twelve-month return on equity of 374.04% and a negative net margin of 571.20%. During the same quarter last year, the company earned ($0.01) earnings per share.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Veru's major shareholders?

Veru's stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (4.06%), Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.42%), Octagon Capital Advisors LP (2.76%), AIGH Capital Management LLC (2.50%) and Worth Venture Partners LLC (0.91%). Insiders that own company stock include Harry Fisch, Lucy Lu and Mario Eisenberger.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERU) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners